Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume

February 13th 2025

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

Obe-Cel Is Associated With Improved Outcomes in R/R B-ALL With Low-Risk CAR-HT Scores

February 13th 2025

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

Obe-Cel Represents a Unique CAR T-Cell Therapy for Patients with Relapsed/Refractory ALL

February 12th 2025

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

February 12th 2025

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer

February 12th 2025

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

First-of-Its-Kind Supportive Oncology Program Offers Unique Training Opportunity for Fellows

February 11th 2025

The Christie NHS Foundation Trust has created a supportive oncology program to train fellows and offer services for patients living with cancer.

Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models

February 10th 2025

Alisertib plus ibrutinib and rituximab showed anti-tumor activity in mantle cell lymphoma in a preclinical study.

Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk

February 7th 2025

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

Envafolimab Plus Suvemcitug and FOLFIRI Shows Early Efficacy, Tolerability in Second-Line CRC

February 7th 2025

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

AI-Enabled Chatbot Replicates Efficacy of SOC Approaches in Aiding Receipt of Cancer Genetic Testing

February 6th 2025

A chatbot-based approach was equivalent to SOC pretest cancer genetic services and genetic testing among individuals eligible for cancer genetic testing.

Eribulin Proves Noninferior to Taxane as Combination Partner With Trastuzumab and Pertuzumab in HER2+ Breast Cancer

February 6th 2025

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer

February 5th 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer

February 5th 2025

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

Serplulimab Plus Chemotherapy Wins EU Approval for Treatment-Naive ES-SCLC

February 5th 2025

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Quadruplet Regimens Stand Strong in Newly Diagnosed Multiple Myeloma

February 4th 2025

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

February 3rd 2025

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.